Clinical Trial Update: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating panitumumab with nab-paclitaxel and carboplatin for HER2-negative inflammatory breast cancer has completed recruitment with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Panitumumab (panitumumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-09-21